Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30756402 | 0.80 | ENPP1 (0.33) | ALDH1A1LMNANPC1ENPP1SMN1; SMN2 | |
| SCHEMBL18900238 | 0.79 | S1PR4 (0.38) | S1PR4NOTUMALDH1A1MAPTPKM | |
| SCHEMBL16841158 | 0.77 | PKM (0.36) | S1PR4ALDH1A1MAPTPKMLMNA | |
| SCHEMBL25986789 | 0.77 | HRH4 (0.34) | S1PR4ALDH1A1MAPTPKMTDP1 | |
| SCHEMBL31658737 | 0.76 | HDAC1 (0.31) | — | |
| SCHEMBL1370741 | 0.76 | — | — | |
| SCHEMBL558512 | 0.75 | PRKCE (0.34) | S1PR4KMOALDH1A1MAPTPKM | |
| SCHEMBL558322 | 0.75 | CA2 (0.36) | S1PR4KMOALDH1A1PKMLMNA | |
| Methylene Chloride SCHEMBL27807279 | 0.75 | PDE5A (0.33) | S1PR4KMOALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7982137 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-3212625-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | Karus Therapeutics Ltd (GB) | 2017-09-06 | — | — | EP | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-4956366-A | GASTROINTESTINAL DISORDERS, ANTISECRETORY AGENTS FOR GASTRIC ACID SECRETION | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-09-11 | — | — | US | disclosed |
| US-4820708-A | ANTISECRETORY AGENTS; GASTROINTESTINAL DISORDERS | SMITH KLINE & FRENCH LABORATORIES (GB) | 1989-04-11 | — | — | US | disclosed |
| EP-0299389-A2 | Substituted thieno-imidazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors, gastric protecting agents and as medicaments against intestinal inflammation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | disclosed |
| US-4777172-A | ANTIGASTRIC ACID SECRETORY AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| CN-86102398-A | The preparation method of substituted benzimidazole derivative | — | 1986-11-12 | — | — | CN | disclosed |
| EP-0198583-A1 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | S1PR4 1378/4885NOTUM 2506/4885KMO 234/4885 |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | HDAC1, HDAC11, HDAC7 | S1PR4 3946/4885NOTUM 2632/4885KMO 1677/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | S1PR4 1437/4885NOTUM 2611/4885KMO 232/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | S1PR4 2201/4885NOTUM 4202/4885KMO 2352/4885 |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | HDAC1, HDAC11, HDAC7 | S1PR4 3946/4885NOTUM 2632/4885KMO 1677/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | S1PR4 2201/4885NOTUM 4202/4885KMO 2352/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | S1PR4 1378/4885NOTUM 2506/4885KMO 234/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | S1PR4 1668/4885NOTUM 4556/4885KMO 1685/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | S1PR4 1668/4885NOTUM 4556/4885KMO 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.